All In Biotech

Drug Trial Radar · NCT02658890

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Aug 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 627 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

627

Actual

Start

Apr 14, 2016

Primary completion

Oct 26, 2021

Study completion Oct 26, 2021

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 20, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab and Ipilimumab in this patient population will also be assessed.

Conditions

  • Advanced Cancer
  • Melanoma
  • Non-Small Cell Lung Cancer

Interventions

  • BMS-986205Drug

  • NivolumabDrug

  • IpilimumabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With AEs, SAEs, AEs Leading to Discontinuation and DeathsTime frame: From first dose to 100 days after last dose (up to 15 months)
  2. Number of Treated Participant With Laboratory Abnormalities - ThyroidTime frame: From first dose to 100 days after last dose (up to 15 months)
  3. Number of Treated Participant With Laboratory Abnormalities - LiverTime frame: From first dose to 100 days after last dose (up to 15 months)
  4. Number of Participants With a Best Overall Response (BOR) - Parts 2 and 3Time frame: From first dose to the last tumor assessment prior to subsequent therapy (up to a maximum of 185 weeks)
  5. Percentage of Participants With an Objective Response Rate (ORR)- Parts 2 and 3Time frame: From first dose to the last tumor assessment prior to subsequent therapy (up to a maximum of 185 weeks)
  6. Median Duration of Response (DoR) - Parts 2 and 3Time frame: From first dose to the date of disease progression, death, or until participants withdraw from the study, whichever occurs first (up to a maximum of 185 weeks)
  7. Progression Free Survival Rate (PFSR) at 24 Weeks - Parts 2 and 3Time frame: At 24 weeks after first dose
  8. Progression Free Survival Rate (PFSR) at 1 Year - Parts 2 and 3Time frame: At 1 year
  9. Progression Free Survival Rate (PFSR) at 2 Years - Parts 2 and 3Time frame: At 2 years

Locations

47 sites in 11 countries. Site status is shown where the registry gives one.

  • Local Institution - 0028

    Tucson, Arizona

  • Local Institution - 0026

    La Jolla, California

  • Local Institution - 0035

    Tampa, Florida

  • Local Institution - 0005

    Atlanta, Georgia

  • Local Institution - 0048

    Atlanta, Georgia

  • Local Institution - 0027

    Chicago, Illinois

  • Local Institution - 0051

    Lutherville, Maryland

  • Local Institution - 0049

    Detroit, Michigan

  • Local Institution - 0006

    St Louis, Missouri

  • Local Institution - 0033

    Hackensack, New Jersey

  • Local Institution - 0041

    New York, New York

  • Local Institution - 0030

    Cleveland, Ohio

  • Local Institution - 0034

    Philadelphia, Pennsylvania

  • Local Institution - 0057

    Pittsburgh, Pennsylvania

  • Local Institution - 0043

    Nashville, Tennessee

  • Local Institution - 0045

    North Sydney, New South Wales, Australia

  • Local Institution - 0029

    Sydney, New South Wales, Australia

  • Local Institution - 0046

    Westmead, New South Wales, Australia

  • Local Institution - 0044

    Brisbane, Queensland, Australia

  • Local Institution - 0008

    Clayton, Victoria, Australia

  • Local Institution - 0004

    Melbourne, Victoria, Australia

  • Local Institution - 0047

    Nedlands, Western Australia, Australia

  • Local Institution - 0003

    Edmonton, Alberta, Canada

  • Local Institution - 0002

    Vancouver, British Columbia, Canada

  • Local Institution - 0001

    Toronto, Ontario, Canada

  • Local Institution

    Greenfield Park, Quebec, Canada

  • Local Institution - 0036

    Montreal, Quebec, Canada

  • Local Institution - 0059

    Helsinki, Finland

  • Local Institution - 0040

    Lille, France

  • Local Institution - 0024

    Lyon, France

  • Local Institution - 0053

    Marseille, France

  • Local Institution - 0052

    Nantes, France

  • Local Institution - 0025

    Paris, France

  • Local Institution - 0023

    Toulouse, France

  • Local Institution - 0022

    Villejuif, France

  • Local Institution - 0019

    Essen, Germany

  • Local Institution - 0013

    Heilbronn, Germany

  • Local Institution - 0010

    Milan, Italy

  • Local Institution - 0011

    Milan, Italy

  • Local Institution - 0012

    Milan, Italy

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.